Welcome to Dwaey, specifically on Dextrose 25% page.
This medicine contains important and useful components, as it consists of
Dextrose 25% is available in the market in concentration.
Dextrose 25%
Dextrose 25% is a concentrated solution of glucose that should be used with caution in patients with certain underlying medical conditions. Patients with uncontrolled diabetes, hyperglycemia, or insulin resistance may experience a rapid increase in blood glucose levels when administered Dextrose 25%, which can exacerbate symptoms of hyperglycemia such as excessive thirst, fatigue, and frequent urination. It is essential to monitor blood glucose levels frequently during treatment to prevent complications like diabetic ketoacidosis or hyperosmolar hyperglycemic state (HHS).
For pregnant women, Dextrose 25% should be used only when necessary, as excessive glucose can cross the placenta and potentially affect both maternal and fetal health. Pregnant women with diabetes or gestational diabetes need careful monitoring of blood glucose levels to prevent harm to the fetus. Similarly, breastfeeding mothers should be cautious, as dextrose can be excreted in breast milk, potentially affecting the infant’s glucose metabolism.
Patients with compromised renal function should use Dextrose 25% with care, as impaired kidneys may struggle to excrete excess glucose, leading to fluid overload or electrolyte imbalances. In patients with heart failure or fluid retention, Dextrose 25% can contribute to worsening symptoms due to its hyperosmolar nature. Frequent monitoring of renal function, electrolytes, and fluid balance is essential during therapy with this solution.
Dextrose 25% is primarily used for the rapid treatment of moderate to severe hypoglycemia in patients who are unable to consume glucose orally. It is particularly useful in emergency medical situations such as in patients with diabetic emergencies (e.g., insulin overdose), critically ill patients, or patients undergoing certain medical procedures where hypoglycemia is a risk. Dextrose 25% is typically administered intravenously, allowing for rapid absorption and quick elevation of blood glucose levels, thus preventing potentially dangerous complications like seizures, confusion, or loss of consciousness.
In addition to treating hypoglycemia, Dextrose 25% can be used in fluid resuscitation therapy for patients experiencing shock, trauma, or other critical illnesses. The solution also serves as an energy source for critically ill patients or those on parenteral nutrition, where glucose supplementation is needed but oral intake is not feasible.
Dextrose 25% may be used off-label in various medical conditions requiring rapid glucose infusion or fluid resuscitation, such as during surgeries, certain types of sepsis, or in patients undergoing intensive care for conditions that demand glucose as a source of rapid energy.
Dextrose 25% should be avoided in patients with severe hyperglycemia or uncontrolled diabetes, as the high glucose concentration may further elevate blood glucose levels, leading to hyperglycemic emergencies like diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS). It is also contraindicated in individuals with known hypersensitivity to dextrose or any of the other components of the solution.
This solution should be used with caution or avoided in patients with renal failure or severe heart conditions, such as congestive heart failure (CHF), where the risk of fluid overload is a concern. Dextrose 25% can exacerbate fluid retention, especially when administered in large volumes, potentially leading to worsened cardiovascular symptoms.
Patients with metabolic disorders, such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, should also avoid Dextrose 25%, as rapid increases in blood glucose can trigger hemolysis in susceptible individuals. Neonates and infants should generally avoid this high concentration of glucose due to their immature glucose-regulation systems, which may increase the risk of hyperglycemia or fluid imbalance.
The most common side effects associated with Dextrose 25% are primarily related to the rapid infusion of a hyperosmolar solution, including hyperglycemia. Symptoms of hyperglycemia include excessive thirst, fatigue, frequent urination, blurred vision, and headache. In more severe cases, prolonged or uncontrolled hyperglycemia may lead to diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), both of which require immediate medical attention.
Fluid overload is another significant concern, especially when large volumes of Dextrose 25% are infused. Patients, particularly those with heart failure, renal impairment, or other conditions that impair fluid balance, may develop edema (swelling), hypertension, or worsened pulmonary edema, which can lead to difficulty breathing and further cardiovascular complications.
Other infusion-related reactions may include vein irritation, pain at the injection site, or the development of thrombophlebitis (inflammation of the veins). These reactions are more likely when Dextrose 25% is administered through a peripheral vein. Electrolyte disturbances, such as hypernatremia (elevated sodium levels) or hypokalemia (low potassium levels), can also occur, particularly if the solution is administered rapidly or in large amounts.
3
Dextrose 25% works by rapidly increasing blood glucose levels when infused intravenously. Upon administration, dextrose is quickly absorbed into the bloodstream, where it is transported to various tissues and cells for energy production. The body’s cells, particularly those in the brain, muscles, and other high-energy-demand organs, utilize glucose as a primary energy source.
The solution’s high concentration of glucose makes it especially effective in emergency situations, such as severe hypoglycemia, where rapid elevation of blood glucose is needed to prevent symptoms like confusion, seizures, or loss of consciousness. Once in the bloodstream, glucose triggers the release of insulin from the pancreas, which facilitates the uptake of glucose into cells and maintains blood glucose homeostasis.
The osmotic properties of Dextrose 25% also help in fluid resuscitation, as glucose can draw water into the bloodstream. This can be beneficial in critical care situations, such as shock or trauma, where both glucose and circulatory volume need to be replenished quickly.
Dextrose 25% can interact with several drugs, particularly those that influence blood glucose levels. Corticosteroids, thiazide diuretics, and certain adrenergic drugs (e.g., epinephrine) can increase blood glucose levels, and when used in conjunction with Dextrose 25%, may lead to exacerbated hyperglycemia. In such cases, careful blood glucose monitoring and adjustments to insulin or oral hypoglycemic agents may be required.
Insulin and other glucose-lowering agents may need to be adjusted when administering Dextrose 25%, as the glucose infusion can counteract their effects. It is important to monitor the patient’s blood glucose levels regularly to prevent both hypoglycemia and hyperglycemia.
There may also be electrolyte imbalances when using Dextrose 25% in combination with other fluids or medications that affect fluid balance, such as potassium supplements or diuretics. The hyperosmolar nature of Dextrose 25% could exacerbate shifts in electrolytes, especially potassium, leading to either hypokalemia or hyperkalemia. Monitoring electrolyte levels is crucial when this solution is administered alongside other treatments.
The typical adult dose of Dextrose 25% for hypoglycemia is 20-50 mL intravenously, depending on the severity of the hypoglycemic episode. The exact dose should be adjusted based on the patient's clinical condition, blood glucose levels, and response to treatment. In emergency situations, an initial bolus of 25 mL of Dextrose 25% (equivalent to 5 grams of glucose) is commonly administered. The dose may be repeated if necessary, depending on the patient's glucose response.
For patients requiring fluid resuscitation, Dextrose 25% is generally administered as part of a larger intravenous fluid regimen. The infusion rate can range from 100 to 200 mL per hour, but it should be tailored to the patient's condition and response. The infusion should not exceed 1 g/kg/min to avoid complications such as hyperglycemia, fluid overload, or electrolyte disturbances.
Dextrose 25% should be used cautiously in pediatric patients, particularly infants and neonates, due to the high glucose concentration. The typical pediatric dose for severe hypoglycemia is generally calculated based on body weight, with an initial dose ranging from 2-5 mL/kg of body weight administered intravenously. This dose provides an adequate amount of glucose without overwhelming the child’s ability to regulate blood glucose.
In neonates, Dextrose 25% is usually avoided due to the high glucose concentration, and more dilute solutions (e.g., Dextrose 10%) are typically used to prevent hyperglycemia and metabolic complications. Close monitoring of blood glucose levels, electrolytes, and overall fluid balance is essential during treatment to prevent adverse effects such as hyperglycemia, fluid overload, or electrolyte disturbances.
Patients with renal impairment should receive Dextrose 25% with caution, as the kidneys are responsible for excreting excess glucose. In patients with reduced renal function, the administration of high concentrations of glucose may lead to fluid retention, hyperglycemia, and electrolyte imbalances. The infusion rate and total volume of Dextrose 25% should be reduced in these patients, and close monitoring of renal function (e.g., serum creatinine and glomerular filtration rate), blood glucose levels, and electrolytes is necessary during treatment.
In patients with severe renal failure or those undergoing dialysis, the use of Dextrose 25% should generally be avoided or administered with extreme caution due to the risk of fluid overload and difficulty in clearing the excess glucose from the bloodstream. For these patients, alternative glucose solutions with lower concentrations or more gradual glucose supplementation may be preferable.
Not available in a medicine form yet